相关实验视频

Updated: Jun 27, 2025

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

亚司匹林用于低收入和中等收入国家预防产前症:注意差距

Ellen Kupka^{1,2,3,4,5,6,7,8,9,10}, James M Roberts^{1,2,3,4,5,6,7,8,9,10}, Zaleha A Mahdy^{1,2,3,4,5,6,7,8,9,10}

¹Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg (Drs Kupka and Bergman), Sweden.

AJOG global reports

|May 2, 2024

概括

低剂量阿司匹林可能会降低妊娠前的风险,但在低收入国家,其有效性和安全性仍然不清楚,特别是在妊娠前和产后出血方面. 需要更多的研究来优化其使用.

科学领域:

产科和妇科产科和妇科
孕产妇和胎儿医学孕产妇和胎儿医学
全球健康全球健康

背景情况:

在全球范围内,孕前是导致孕产妇和新生儿死亡的主要原因.
低剂量阿司匹林是一种潜在的预防措施,但其机制和最佳使用尚未完全理解.
目前的查和治疗策略在很大程度上基于高收入环境,在低资源环境中适用性有限.

研究的目的:

审查目前关于低剂量阿司匹林预防产前的知识.
确定低收入和中等收入国家 (LMICs) 的阿司匹林使用知识差距和挑战.
建议未来的研究方向,以便在LMICs中安全有效地实施阿司匹林.

主要方法:

系统审查现有的关于子宫前,阿司匹林,查和危险因素的文献.
对在高收入与低资源环境中进行的研究进行分析.
评估关于阿司匹林治疗早产和早产前疗效的证据.
评估阿司匹林的安全性,包括产后出血的风险.

主要成果:

阿司匹林的预防作用主要观察到早产前;对早产前的影响很小.
查算法和早期阿司匹林启动在LMICs面临挑战,因为不充分的产前护理.
随着阿司匹林的使用,产后出血的潜在风险增加需要在LMIC中仔细考虑.
有限的数据存在于最佳阿司匹林剂量和患者在不同环境中的坚持.

结论:

显著的知识差距阻碍了低剂量阿司匹林在LMIC中安全和广泛使用以预防产前.
进一步的研究至关重要,以解决产前的有效性,安全问题 (产后出血),最佳剂量和坚持.
需要量身定制的战略,在LMIC医疗保健系统的背景下有效地实施阿司匹林.

关键词:

阿司匹林的剂量阿司匹林的剂量阿司匹林在妊娠前症中使用.低收入和中等收入国家.低剂量阿司匹林的使用.低资源设置中的低资源设置孕产妇和产周死亡率孕前预防预防孕前孕前的查孕前的查

更多相关视频

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...